<\/p>\n
\n Drugmakers have developed pill versions of GLP-1 medicines to treat obesity.
\n <\/p>\n
David J. Phillip\/AP<\/p>\n
<\/b>
\n hide caption<\/b><\/b>\n <\/p>\n
toggle caption<\/b><\/b><\/p>\n
David J. Phillip\/AP<\/p>\n
You may have heard of Ozempic, and other GLP-1 drugs. They’re everywhere. But weekly injections, cost, and insurance complications mean they’re not for everyone.<\/p>\n
That’s why there’s a lot of excitement around two new pill forms of the drug.<\/p>\n
The first is a Wegovy pill that’s expected to win FDA approval by the end of the year. Plus another kind of obesity pill that could be right behind it.<\/p>\n
The human body naturally makes a hormone called GLP-1, or Glucagon-Like Peptide-1. It helps signal fullness and stimulate insulin secretion in the body. GLP-1 drugs do something similar \u2013 but they stick around in the body for longer.<\/p>\n
Check out more of NPR’s <\/strong>coverage <\/strong><\/a>about GLP-1s.<\/strong><\/p>\n Interested in more health stories? Email us your question at shortwave@npr.org<\/a>.<\/p>\n Listen to every episode of Short Wave sponsor-free and support our work at NPR by signing up for Short Wave+ at plus.npr.org\/shortwave<\/a>.<\/p>\n Listen to Short Wave on Spotify<\/a> and Apple Podcasts<\/a>.<\/p>\n This episode was produced by Rachel Carlson. It was edited by Rebecca Ramirez. Tyler Jones checked the facts. The audio engineer was Kwesi Lee.\u00a0\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"Drugmakers have developed pill versions of GLP-1 medicines to treat obesity. David J. Phillip\/AP hide caption toggle caption…\n","protected":false},"author":3,"featured_media":458008,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[210,1060,67,132,68],"class_list":{"0":"post-458007","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-health","9":"tag-medication","10":"tag-united-states","11":"tag-unitedstates","12":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115746906217882936","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/458007","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=458007"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/458007\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/458008"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=458007"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=458007"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=458007"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}